Decrease of Serum Angiotensin Converting Enzyme Levels Upon Telbivudine Treatment for Chronic Hepatitis B Virus Infection and Negative Correlations Between the Enzyme Levels and Estimated Glumerular Filtration Rates

AUTHORS

Kung-Hao Liang 1 , * , Yi-Cheng Chen 1 , Chao-Wei Hsu 1 , Ming-Ling Chang 1 , Chau-Ting Yeh 2 , *

1 Liver Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan

2 Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan

Corresponding Authors:

How to Cite: Liang K, Chen Y, Hsu C, Chang M, Yeh C. Decrease of Serum Angiotensin Converting Enzyme Levels Upon Telbivudine Treatment for Chronic Hepatitis B Virus Infection and Negative Correlations Between the Enzyme Levels and Estimated Glumerular Filtration Rates, Hepat Mon. 2013 ; 14(1):15074. doi: 10.5812/hepatmon.15074.

ARTICLE INFORMATION

Hepatitis Monthly: 14 (1); 15074
Published Online: January 30, 2014
Article Type: Research Article
Received: September 26, 2013
Accepted: October 31, 2013
Crossmark

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: During antiviral therapy for chronic hepatitis B, renal function impairment could be a critical concern when oral nucleot(s)ide analogues were used. Paradoxically, long-term telbivudine treatment was associated with an increase of estimated glomerular filtration rate (eGFR) through unknown mechanisms.

Objectives: We aimed to investigate changes in serum protein abundances associated with renal function in response to antiviral treatments.

Materials and Methods: Primarily, a transcriptomic assay was performed to identify differentially expressed genes in peripheral blood cells caused by the telbivudine treatment. Two genes coding angiotensin converting enzyme (ACE) and complement factor H (CFH) were screened from 14 candidate renal function-related genes. ACE and CFH production were further investigated using enzyme-linked immunoassays.

Results: Verification studies showed no significant change of serum CFH levels, but there was a significant reduction of serum ACE levels by continuous telbivudine treatment for 330.00 0.85 days (34 patients; paired t-test, P = 0.022). Serum HBV DNA and ALT levels also decreased (P = 0.008 and < 0.001, respectively). A significant increase in eGFR was found (33 patients, paired t-test, P = 0.002) at 708.64 31.63 days. Patients eGFRs were negatively correlated with serum ACE levels (r = -0.375, P = 0.002) but not with serum HBV DNA and ALT levels (P = 0.241 and 0.088 respectively). Significant decreases of the ACE levels were also observed upon entecavir treatment (20 patients; paired t-test, P = 0.020) at 412.88 36.92 days. No significant correlation was found between serum ACE levels and eGFRs (r = -0.239, P = 0.138) in entecavir-treated patients.

Conclusions: We discovered a consistent reduction of serum ACE levels by two oral antiviral monotherapies, entecavir and telbivudine. Serum ACE levels were negatively correlated with eGFRs in telbivudine treated patients.

Keywords

Hepatitis B Nucleosides Antiviral Agents Kidney

© 2013, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: